Culturally Tailored Diabetes Self-Management Education and Support Programs in Black African and Caribbean Adults With Type 2 Diabetes (HEAL-D): Protocol for a Multicenter, Pragmatic Randomized Controlled Trial.

IF 1.5 Q3 HEALTH CARE SCIENCES & SERVICES
Louise M Goff, Drusus A Johnson, Vicky Bell, Susan Blyden, Peter Bower, Jeremy Dale, Tess Harris, Andrew Healey, Eleanor Hoverd, Huajie Jin, Tony Kelly, Carol Rivas, Clare Robinson, Jayne Thorpe, Sandra Tomlinson, Michael Ussher, Charlotte Wahlich, Barbara McGowan
{"title":"Culturally Tailored Diabetes Self-Management Education and Support Programs in Black African and Caribbean Adults With Type 2 Diabetes (HEAL-D): Protocol for a Multicenter, Pragmatic Randomized Controlled Trial.","authors":"Louise M Goff, Drusus A Johnson, Vicky Bell, Susan Blyden, Peter Bower, Jeremy Dale, Tess Harris, Andrew Healey, Eleanor Hoverd, Huajie Jin, Tony Kelly, Carol Rivas, Clare Robinson, Jayne Thorpe, Sandra Tomlinson, Michael Ussher, Charlotte Wahlich, Barbara McGowan","doi":"10.2196/71861","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>People of Black African and Black Caribbean ethnicity experience higher rates and poorer outcomes of type 2 diabetes (T2D) than people of White European ethnicity; these inequalities are compounded by poor healthcare access. Cultural tailoring of diabetes self-management education and support (DSMES) programs has the potential to improve healthcare engagement and clinical outcomes for ethnic minority groups. Healthy Eating & Active Lifestyles for Diabetes (HEAL-D) is a co-designed, culturally tailored group-based DSMES program for adults of Black African and Black Caribbean ethnicity.</p><p><strong>Objective: </strong>This trial aims to evaluate the clinical and cost effectiveness of the HEAL-D intervention, compared to standard DSMES programs, in Black African and Black Caribbean adults living with T2D.</p><p><strong>Methods: </strong>A 24-month, multicenter, pragmatic, open-label, 2-arm, parallel-group, individually randomized group treatment trial will be conducted, with primary end point (glycated hemoglobin [HbA<sub>1c</sub>]) assessment at 12 months. Black African and Black Caribbean adults with T2D (n=300), recruited from 3 to 5 centers in the United Kingdom (including London, West Midlands, and Greater Manchester), will be randomized in a 1:1 ratio to HEAL-D (intervention) or a standard DSMES program (control). HbA<sub>1c</sub>, blood lipids, anthropometric outcomes, blood pressure, physical activity, and patient-reported outcome measures relating to psychological well-being and self-management support, lifestyle behaviors, and health economics will be collected at baseline and follow-up visits (6, 12, and 24 months). Cost-effectiveness will be assessed through a cost-utility analysis conducted from a health and social care perspective. A mixed methods process evaluation will provide a formative evaluation of delivery, intervention fidelity, and implementation of HEAL-D, and an embedded study within a project will assess the impact of multiple long-term conditions on uptake of, and engagement with HEAL-D, and the impact of HEAL-D on multiple long-term conditions. The trial received Research Authority and Research Ethics Council approval on April 22, 2024.</p><p><strong>Results: </strong>Funding began in August 2023. Site \"green light\" was received on August 15, 2024, for London; November 29, 2024, for Manchester; and January 31, 2025, for the West Midlands. Recruitment commenced in August 2024 and is due to run for 11 months. As of March 26, 2025, a total of 76 participants have consented. Last patient, last visit is expected in June 2027; primary data analysis is expected to begin in July 2027. Final results are anticipated to be available in September 2027, and publication is expected by the end of 2027.</p><p><strong>Conclusions: </strong>The HEAL-D trial will address whether a culturally tailored DSMES program, provided in-person or via videoconferencing, is clinically and cost-effective compared to standard DSMES at improving diabetes management in Black African and Black Caribbean adults. If effective, this would provide an evidence-based model of equitable DSMES services and improve the implementation of healthcare programs for ethnic minority groups.</p><p><strong>Trial registration: </strong>ISRCTN 1434448; https://www.isrctn.com/ISRCTN14344948.</p><p><strong>International registered report identifier (irrid): </strong>DERR1-10.2196/71861.</p>","PeriodicalId":14755,"journal":{"name":"JMIR Research Protocols","volume":"14 ","pages":"e71861"},"PeriodicalIF":1.5000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JMIR Research Protocols","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2196/71861","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: People of Black African and Black Caribbean ethnicity experience higher rates and poorer outcomes of type 2 diabetes (T2D) than people of White European ethnicity; these inequalities are compounded by poor healthcare access. Cultural tailoring of diabetes self-management education and support (DSMES) programs has the potential to improve healthcare engagement and clinical outcomes for ethnic minority groups. Healthy Eating & Active Lifestyles for Diabetes (HEAL-D) is a co-designed, culturally tailored group-based DSMES program for adults of Black African and Black Caribbean ethnicity.

Objective: This trial aims to evaluate the clinical and cost effectiveness of the HEAL-D intervention, compared to standard DSMES programs, in Black African and Black Caribbean adults living with T2D.

Methods: A 24-month, multicenter, pragmatic, open-label, 2-arm, parallel-group, individually randomized group treatment trial will be conducted, with primary end point (glycated hemoglobin [HbA1c]) assessment at 12 months. Black African and Black Caribbean adults with T2D (n=300), recruited from 3 to 5 centers in the United Kingdom (including London, West Midlands, and Greater Manchester), will be randomized in a 1:1 ratio to HEAL-D (intervention) or a standard DSMES program (control). HbA1c, blood lipids, anthropometric outcomes, blood pressure, physical activity, and patient-reported outcome measures relating to psychological well-being and self-management support, lifestyle behaviors, and health economics will be collected at baseline and follow-up visits (6, 12, and 24 months). Cost-effectiveness will be assessed through a cost-utility analysis conducted from a health and social care perspective. A mixed methods process evaluation will provide a formative evaluation of delivery, intervention fidelity, and implementation of HEAL-D, and an embedded study within a project will assess the impact of multiple long-term conditions on uptake of, and engagement with HEAL-D, and the impact of HEAL-D on multiple long-term conditions. The trial received Research Authority and Research Ethics Council approval on April 22, 2024.

Results: Funding began in August 2023. Site "green light" was received on August 15, 2024, for London; November 29, 2024, for Manchester; and January 31, 2025, for the West Midlands. Recruitment commenced in August 2024 and is due to run for 11 months. As of March 26, 2025, a total of 76 participants have consented. Last patient, last visit is expected in June 2027; primary data analysis is expected to begin in July 2027. Final results are anticipated to be available in September 2027, and publication is expected by the end of 2027.

Conclusions: The HEAL-D trial will address whether a culturally tailored DSMES program, provided in-person or via videoconferencing, is clinically and cost-effective compared to standard DSMES at improving diabetes management in Black African and Black Caribbean adults. If effective, this would provide an evidence-based model of equitable DSMES services and improve the implementation of healthcare programs for ethnic minority groups.

Trial registration: ISRCTN 1434448; https://www.isrctn.com/ISRCTN14344948.

International registered report identifier (irrid): DERR1-10.2196/71861.

非洲和加勒比地区黑人成人2型糖尿病患者的文化定制糖尿病自我管理教育和支持项目(heald):一项多中心、实用的随机对照试验方案
背景:非洲黑人和加勒比黑人的2型糖尿病(T2D)发病率高于欧洲白人,预后较差;这些不平等现象因医疗保健机会不足而更加严重。糖尿病自我管理教育和支持(DSMES)项目的文化定制有可能改善少数民族群体的医疗保健参与和临床结果。健康饮食和积极生活方式促进糖尿病(heald)是一项针对非洲黑人和加勒比黑人种族的成年人共同设计的、基于文化的群体DSMES方案。目的:本试验旨在评估与标准DSMES计划相比,heald干预在非洲黑人和加勒比黑人成人T2D患者中的临床和成本效益。方法:将进行一项为期24个月、多中心、实用、开放标签、双组、平行组、单独随机分组的治疗试验,在12个月时评估主要终点(糖化血红蛋白[HbA1c])。从英国(包括伦敦、西米德兰兹郡和大曼彻斯特)的3至5个中心招募患有T2D的非洲黑人和加勒比黑人成人(n=300),将按1:1的比例随机分配到heald(干预)或标准DSMES计划(对照组)。HbA1c、血脂、人体测量结果、血压、体力活动和患者报告的与心理健康和自我管理支持、生活方式行为和健康经济学相关的结果测量将在基线和随访(6、12和24个月)时收集。将通过从保健和社会保健角度进行的成本效用分析来评估成本效益。混合方法过程评估将提供对医疗保健- d的交付、干预保真度和实施的形成性评估,项目内的嵌入式研究将评估多种长期条件对医疗保健- d的吸收和参与的影响,以及医疗保健- d对多种长期条件的影响。该试验于2024年4月22日获得了研究权威和研究伦理委员会的批准。结果:资金于2023年8月开始。2024年8月15日,伦敦获得了场地“绿灯”;2024年11月29日,曼彻斯特;2025年1月31日是西米德兰兹郡。招聘于2024年8月开始,预计将持续11个月。截至2025年3月26日,共有76名参与者表示同意。最后一位患者,最后一次就诊预计在2027年6月;初步数据分析预计将于2027年7月开始。最终结果预计将于2027年9月公布,预计将于2027年底公布。结论:与标准的DSMES相比,HEAL-D试验将探讨在改善非洲黑人和加勒比黑人成人的糖尿病管理方面,一个文化上适合的DSMES项目(面对面或通过视频会议提供)是否具有临床和成本效益。如果有效,这将为公平的DSMES服务提供一个基于证据的模式,并改善少数民族群体医疗保健计划的实施。试验注册:ISRCTN 1434448;https://www.isrctn.com/ISRCTN14344948.International注册报告标识符(irrid): DERR1-10.2196/71861。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.40
自引率
5.90%
发文量
414
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信